Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea

Fineline Cube Apr 9, 2026
Company Deals

Grand Pharma Partners with HKU on Anti‑Infective Drug Discovery – Exclusive License Deal Targets Novel Antibacterial Therapies

Fineline Cube Apr 9, 2026
Company Deals

Wuhan Ammunition Life-tech Files Hong Kong IPO Prospectus, Pioneering Methylation-Based Early Cancer Detection with Liver and Urothelial Cancer Tests

Fineline Cube Apr 8, 2026
Company Deals

Gilead Sciences to Acquire Tubulis for $3.15B Upfront, Adding Next-Generation ADCs TUB-040 and TUB-030 to Oncology Pipeline

Fineline Cube Apr 8, 2026
Company Deals

Biogen Licenses Alloy Therapeutics’ AntiClastic ASO Platform to Advance Next-Generation Antisense Therapy Research

Fineline Cube Apr 8, 2026
Policy / Regulatory

Beijing Unveils 32-Point Framework to Accelerate Healthcare Innovation, AI Integration, and Medical Device Development

Fineline Cube Apr 8, 2026
Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Fineline Cube Apr 9, 2026
Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Fineline Cube Apr 9, 2026
Company Deals

Lexicon Pharmaceuticals Strikes Licensing Deal with Viatris for Global Expansion of Sotagliflozin

Fineline Cube Oct 17, 2024

Lexicon Pharmaceuticals, Inc. (NASDAQ: LXRX) has entered into a licensing agreement with Viatris Inc. (NASDAQ:...

Company Drug

Johnson & Johnson’s Nipocalimab Shows Promise in Treating Adolescent Myasthenia Gravis in Phase II/III Trial

Fineline Cube Oct 17, 2024

Johnson & Johnson (J&J, NYSE: JNJ), a US pharmaceutical giant, has reported encouraging outcomes from...

Policy / Regulatory

NHSA Standardizes NRDL Drug Purchases to Combat Prescription Fraud

Fineline Cube Oct 17, 2024

The National Healthcare Security Administration (NHSA) has issued a notification aimed at standardizing the management...

Policy / Regulatory

Shanxi Province Announces Historic Drug Procurement Batch with 81 Products for 2024

Fineline Cube Oct 17, 2024

On October 16, 2024, Shanxi Province’s drug procurement platform announced a notice regarding the submission...

Company Drug

Alphamab Oncology and CSPC Pharma’s KN026 Phase III Trial for Breast Cancer Gets NMPA Approval

Fineline Cube Oct 17, 2024

Alphamab Oncology (HKG: 9966) and CSPC Pharma (HKG: 1093) have jointly announced that their Phase...

Company Deals

Boehringer Ingelheim Pledges USD 5 Million to WHO Foundation for Global Healthcare Advancement

Fineline Cube Oct 16, 2024

Boehringer Ingelheim (BI), a leading German pharmaceutical company, has joined forces with the World Health...

Company

J&J Reports Q3 2024 Revenue Growth, Raises Full-Year Guidance on Strong Pipeline Progress

Fineline Cube Oct 16, 2024

Johnson & Johnson (J&J, NYSE: JNJ) has released its financial report for the third quarter...

Company Drug

Shanghai Junshi Biosciences’ Toripalimab Wins Marketing Approvals in India and Hong Kong for Nasopharyngeal Carcinoma

Fineline Cube Oct 16, 2024

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biotech company based in...

Company

Eli Lilly Launches Medical Innovation Center and Gateway Labs in Beijing to Accelerate Clinical Trials and R&D

Fineline Cube Oct 16, 2024

Eli Lilly & Co. (NYSE: LLY), a leading pharmaceutical corporation in the US, has announced...

Company Drug

Jiangsu Hengrui Resubmits Application for Camrelizumab Combo in HCC to FDA

Fineline Cube Oct 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a prominent pharmaceutical company based in China, has...

Company Drug

Innovec Biotherapeutics’ IVB103 Gene Therapy for nAMD Receives Clinical Trial Approval from China’s CDE

Fineline Cube Oct 16, 2024

Beijing InnoVec Biotherapeutics Inc., a leading gene therapy company based in China, has announced that...

Company Drug

Aficamten Market Filing Accepted by China’s CDE for Hypertrophic Cardiomyopathy Treatment

Fineline Cube Oct 16, 2024

CORXEL, formerly known as Ji Xing Pharmaceuticals and Cytokinetics Inc (CYTK, NASDAQ: CYTK) have achieved...

Company Drug

Jiangsu Hengrui’s Hetrombopag Olamine Receives NMPA Review for Severe Aplastic Anemia Indication

Fineline Cube Oct 16, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd (SHA: 600276), a leading pharmaceutical company based in China, has...

Company Drug

Hinova Pharmaceuticals Gets NMPA Green Light for HP568 Clinical Study in Breast Cancer

Fineline Cube Oct 16, 2024

Hinova Pharmaceuticals Inc. (SHA: 688302), a biotech firm based in Chengdu, has announced that it...

Company Deals

Boehringer Ingelheim Partners with Circle Pharma to Develop First-in-Class Cyclin Inhibitor

Fineline Cube Oct 16, 2024

Boehringer Ingelheim (BI), a leading German pharmaceutical company, has announced a research collaboration and license...

Company Deals

TenNor Therapeutics Secures USD 42.16 Million in Series E Financing for Antibacterial Pipeline

Fineline Cube Oct 16, 2024

TenNor Therapeutics, a clinical-stage pharmaceutical company based in China, has announced the successful completion of...

Company Drug

Huadong Medicine Gets NMPA Green Light for BCMA-Targeted ADC HDM2027 Phase I/IIa Study

Fineline Cube Oct 16, 2024

Huadong Medicine Co., Ltd (SHE: 000963), a Chinese pharmaceutical company, has announced that it has...

Company Medical Device

Lepu Medical Receives Approval for Noninvasive Blood Glucose Meter NeoGlu 01 in China

Fineline Cube Oct 16, 2024

Lepu Medical Technology (Beijing) Co., Ltd (SHE: 300003), a leading provider of cardiovascular disease solutions...

Company Drug

Leqembi, Alzheimer’s Drug by Eisai and Biogen, Now Covered by Qihuibao Insurance in China

Fineline Cube Oct 15, 2024

Leqembi (lecanemab), an Alzheimer’s disease treatment co-developed by Eisai Co., Ltd (TYO: 4523) and Biogen...

Company Deals

Bayer AG and Meituan Deepen Partnership to Transform Skin Health Market in China

Fineline Cube Oct 15, 2024

Bayer AG (ETR: BAYN), a leading German multinational pharmaceutical and life sciences company, has expanded...

Posts pagination

1 … 265 266 267 … 648

Recent updates

  • Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China
  • Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia
  • Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies
  • GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer
  • Gan & Lee Licenses Bonfaglutide to JW Pharma for $81.1M – Expands GLP‑1 Footprint into South Korea
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Haisco Pharma’s HSK42360 Selected for NMPA SPARK Program – First BRAF V600 Inhibitor for Pediatric Glioma in China

Company Drug

Luye Pharma Doses First Patient in Phase II Study of LY03020 – World’s First Dual‑Target TAAR1/5‑HT2CR Agonist for Schizophrenia

Company Drug

Sino Biopharm Wins FDA Approval for Pan‑KRAS Inhibitor TQB3205 – First‑in‑Human Trial in Advanced Malignancies

Company Drug

GenFleet Therapeutics Secures First‑Ever NMPA Breakthrough Designation for KRAS G12D Inhibitor in Pancreatic Cancer

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.